Eagle Pharmaceuticals (EGRX) Posts Q2 Loss of 21c/Share

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.21), $0.16 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $3.4 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• BofA expects Apple to top analyst expectations on July 30
• Betsey Rhynhart joins Ledyard Financial Group board
• Tempus AI to acquire Personalis in $1.5B stock deal